Taking stock of the drug industry, from the lab to the medicine chest

August 2, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Alex Wong/Getty Images Opinion: Trump gave patients a 'right to try.' It hasn't helped them Donald Trump says the Right to Try Act is "saving thousands and thousands of lives." But almost no one has used it. There's a better option. By Alison Bateman-House and Holly Fernandez Lynch STAT+ | FDA approves innovative T cell immunotherapy for rare soft-tissue cancer The medicine, called Tecelra, is a T cell receptor treatment, an emerging type of immunotherapy showing promise in solid tumors. By Andrew Joseph STAT+ | 23andMe board rejects co-founder Anne Wojcicki's offer to take company private The board said Wojcicki's proposal failed to offer a premium to 23andMe's current stock price and did not have committed financing from other investors. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser